New NIH definitions classify virtually all human brain and behavioral research as clinical trials. The new definitions will change regulatory, reporting, and funding schemes for noninvasive studies such as neuroimaging. Resulting burdens threaten the viability of basic biobehavioral science research.
There are two primary categories of biological research in humans: basic science research, or research aimed at understanding the mechanisms, causal structure, and functioning of the human body (including brain/mind), and clinical research, which primarily aims to apply and expand upon that knowledge for medical purposes. Although the public most obviously reaps the benefits of scientific knowledge when that knowledge is used to improve health outcomes, it is also indisputable that our medical advances have only been made possible by building on a foundation of discoveries in basic science and that the success of the medical technology sector is due in large part to prior investments made in basic research. Both types of research are valuable in their own right, and each type has a distinct kind of scientific structure and dynamic. Until now, each has been recognized as distinct by the public and by our governmental agencies, and each has enjoyed distinct regulatory and funding schemes suited to their differences in modes of discovery, timescales, scope, costs, and risks of research.
That division looks to be collapsing, to the detriment of basic research in the biobehavioral sciences. In 2014, the NIH revised its definition of clinical trials to include experiments that assign human participants to ''interventions,'' where the effect of the intervention has a healthrelated biomedical or behavioral outcome. This new definition of clinical trials encompasses virtually all experimental brain and behavioral research in humans that used to be considered basic research. The new definition is markedly different from the old: a current NIH webpage still defines clinical trials as ''research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans. These studies also may show which medical approaches work best for certain illnesses or groups of people'' (https://www.nhlbi.nih.gov/studies/ clinicaltrials). However, as of January 2018, the new definitions will be enforced, and scientific studies that meet these criteria will be subject to more stringent regulation and approval processes, processes not well suited to the structure of basic science (http://www. sciencemag.org/news/2016/09/nih-aimsbeef-clinical-trial-design-part-new-datasharing-rules). These changes were passed largely under the radar of the academic community, which comprises the bulk of basic biological research, because basic scientists were unaware that changes to clinical regulations, which formerly had only applied to those doing clinical research, would apply now to them. The scientific community is only now becoming aware of the changes and what they portend for their research going forward. While the aim of the changes is ostensibly to improve transparency and efficiency in clinical/pharmaceutical design-laudable goals to be sure-this new definition and the onesize-fits-all strategy that it implies threaten to drastically hobble and even decimate noninvasive basic research studies.
The core problem is the imprecise, sweeping, and logically untenable formulation of what constitutes a clinical trial.
The definitions of clinical trial and associated terms are philosophically unprincipled and ill conceived, and this results in a policy both difficult to implement judiciously because of its lack of clarity and dangerously chilling to basic science if implemented as literally written.
For example, recall that clinical trials are defined as experiments that assign human participants to interventions, where the effect of the intervention has a health-related biomedical or behavioral outcome. According to the NIH definitions, an ''intervention'' is defined as a manipulation of the subject or subject's environment for the purpose of modifying one or more health-related biomedical or behavioral processes and/or endpoints (https://grants.nih.gov/policy/clinical-trials/ case-studies.htm). ''Health-related biomedical or behavioral processes and/or endpoints'' are defined as the pre-specified goal(s) or condition(s) that reflect the effect of one or more interventions on human subjects' biomedical or behavioral status or quality of life. These definitions are patently circular: studying any human action can be counted as a health-related biomedical or behavioral process if one picks one's intervention appropriately, and vice versa. Moreover, what counts as biomedical or behavioral status, or related to quality of life, is entirely open ended. All dispositions to behave are at some level due to aspects of brain function, and if brain function is biomedical, then any hypothesis-driven study with any measurable effect, whether on behavior alone or on brain function, will satisfy the definition, including types of studies that the NIH has explicitly identified in their guidelines as not counting as clinical trials, such as educational studies.
To mitigate the ambiguity of the definition, the NIH provides four questions to determine whether a research project is a clinical trial under the new definition:
1. Does the study involve human participants? 2. Are the participants prospectively assigned to an intervention? 3. Is the study designed to evaluate the effect of the intervention on the participants? 4. Is the effect that will be evaluated a health-related biomedical or behavioral outcome?
Positive answers to these four questions mean that a study counts as a clinical trial.
The NIH offers an array of case studies to help potential applicants determine whether their research counts as a clinical trial. However, these cases are themselves confusing and inconsistent with the provided definitions. Consider, for example, Case 18: ''The study involves the recruitment of healthy volunteers who will perform working memory tasks while an fMRI is performed. It is designed to determine the brain functions involved in working memory.'' Is the effect being evaluated a health-related biomedical or behavioral outcome? Yes, the effect being evaluated-brain function-is a health-related biomedical or behavioral outcome. The study is a clinical trial. This is the most common kind of neuroimaging experiment, so clearly the new definitions mean to catch noninvasive nonclinical neuroimaging studies in their net. Strangely, Case 22 ''involves the recruitment of healthy children who will be presented with a series of learning activities. It is designed to evaluate the children's ability to retain and retrieve specific information.'' This is not deemed a clinical trial, because ''this educational study is evaluating learning activities and has no clear link to health.'' But of course it does, because the learning involves the same biological organ, and because there are very clear correlations between education and health. Given the open-endedness of the term ''health related,'' and the fact that brain function is intimately involved with health, it is not unreasonable to think that learning and education are health related. The salient point is that these are two studies that are essentially equivalent in terms of task, design, and invasiveness. Ironically, the new policy seems to favor the one that aims to tell us less rather than more: the study receiving less scrutiny because it is not classified as a clinical trial will provide no information about how or why something is the case; the study that may increase our understanding of cognition will be saddled with a heavy burden. Moving on, Case 24 is a study that ''involves evaluating different types of printed announcements to identify the best designs for ensuring comprehension and retention of information in adults. Visitors to public libraries will be selected at random and asked to read one of the two announcements and then to take a short survey to elicit their perspectives about readability.'' This is deemed not to be a clinical trial because the answer to question 3 is ''no'': ''the study is designed to learn about participants' opinions on the readability of the different printed announcements. It is not designed to evaluate the effect of the printed material on the participants.'' But, of course, the only way the participants could have opinions about the readability is because of the effect of the printed material on them, so again, one wonders why this isn't a clinical trial. A rational person certainly could see things the other way. The NIH promises that more cases will be forthcoming to further clarify what counts as a clinical trial, but the current crop is not encouraging, and the reason is clear: the definitions upon which interpreters must rely are defective. Unless arbitrary distinctions are going to be made, the new definitions threaten to swallow up anything that is a hypothesis-driven human study involving brain or cognition. And if we, as researchers, have to rely upon arbitrary distinctions, then the process of applying for NIH grants will be perplexing and risky.
If implemented, this new policy will result in significant costs to basic research. The primary worry is that it will stifle discovery science or basic research that is exploratory, nimble, small in scope, fast moving, and potentially large in payoff. History of science shows that the biggest breakthroughs are often fortuitous, and many experiments are dramatically improved by the early recognition of missteps. This kind of science often directs and shapes larger, more formal studies in basic and clinical research. The rigidity imposed by the new system, which requires preregistration of experiments with an instrument geared for larger and more risky clinical studies, will drastically slow the pace of discovery. Unless scientists have the ability to do low-cost pilot studies, they will be forced to curtail the exploratory function of science. The potential regulatory burden is also a concern: in an era where basic research is already reeling from massive funding cuts and lack of support from the highest levels of government, the added costs involved in navigating the more complicated and administrationheavy system may be the death knell for basic brain and cognitive research. Available funding is unlikely to be able to support the additional institutional personnel, time, and resources needed to comply with the additional regulations.
Another worry is that using the same instrument for real clinical trials (i.e., applied medical research) and for what is currently called basic research may have adverse effects on the quality of research, precisely the opposite of what the aims of these changes mean to achieve. Given the extra burdens that running a clinical trial may incur, researchers will be encouraged to design experiments that don't count as clinical trials. The easiest way to do this may be to forego prospective assignment of subjects to interventions-in other words, to abandon controlled, hypothesis-driven experiments in favor of correlational and merely descriptive studies. And since interventions are crucial for discerning causal information and distinguishing it from mere correlation, studies aimed at understanding causal structure-often the most useful kind of information science can provide-will be differentially discouraged. This is another irony, for the aim of the new regulations is to improve the quality of science. The actual effect will likely be to discourage the best science by implicitly encouraging poorly designed and/or unambitious studies. A researcher could also avoid the significant added burdens of being classified as a clinical trial by arguing that the outcome they measure is not health related (which is hard if one does brain research). However, they face a Catch-22, for if they were successful in doing so, it may well undermine their eligibility for funding, as the NIH is unlikely to fund research that is clearly not health related. Thus, far from being an instrument to improve the quality of science overall, the long-term effect of these changes will be detrimental to good science.
It may help to reflect upon the ultimate motivations of the new guidelines in assessing how to proceed. For example, the focus on interventions in the definition of clinical trials is misplaced, for any controlled experiment involves an intervention, and it is the inclusion of this term that brings everything under the rubric of a clinical trial. Certainly what is worrisome or deserving of greater scrutiny is not merely that an experiment is being run, but something about the type of experiment, such as the possible costs/ harms of the intervention in question. For noninvasive neuroimaging methods, such as fMRI and EEG, these are insignificant and do not warrant the increased scrutiny.
What should be clear is that we criticize the means, but not the aim, of these changes. The underlying motivation for the new policy are good ones, and the basic science community would welcome an opportunity to help craft changes in policy that would achieve these goals in a way that would not hinder basic science. Scientists themselves recognize that the lack of venues for the reporting of null results and the paucity of publically available databases are problems that need to be addressed, and some scientists are discussing a separate pathway for registering and reporting studies more suited to the reality of form and constraints of basic science (for examples, see the Open Science Framework, https://cos.io/our-products/open-scienceframework/). Perhaps in conjunction with the NIH, basic scientists could develop a centralized searchable database of null results or a separate pathway for registering studies. Regardless of what practical solutions are developed, one thing that should not stand is the equivalence of basic research with clinical research, for each kind of research is distinct and should be recognized as such, valued for what it is, and held to standards appropriate to the kind of research it is. It would be a shame if basic research were eviscerated in the name of good intentions when the goals of transparency and replicability can be achieved in much less damaging ways.
Interested readers can find the NIH defense of the new definition and the flurry of responses from the research community at: https://nexus.od.nih.gov/all/ 2017/08/11/4-questions-for-researchersand-institutions-involved-in-humansubjects-research/?utm_source=nexus& utm_medium=email&utm_content= nihupdate&utm_campaign=jul17. They can leave a comment at the same site. In addition, a group led by FABBS (Federation of Associations in Behavioral and Brain Sciences) has prepared an open letter to NIH Director Francis Collins, which can be signed here: https://ipetitions. com/petition/open-letter-nih-collins. Efforts are also underway to lobby Congress; more traction could be achieved by contacting your congressperson directly.
More criticisms and new developments are certain to appear in the next weeks. But, for now, it is clear that if this new definition of clinical trials is applied literally, the costs to basic research will be severe and will ultimately discourage the quality of research that the NIH aims to promote. While we applaud the aims of transparency and replicability in science, expanding the definition of a clinical trial is not an instrument well suited to achieving that result, and a one-size-fits-all regulatory treatment for virtually all hypothesisdriven human biobehavioral research will have a devastating effect on noninvasive basic brain research and beyond. The NIH's new tool is crude and sweeping and catches too much in its net, much as overly broad fishing techniques have decimated numerous untargeted and often prized marine species caught unintentionally by nets and longlines, referred to as bycatch. The NIH should quickly reconsider its policy changes before basic research in neuroscience and cognitive science become scientific bycatch.
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